Roche writes off ul­cer­a­tive col­i­tis por­tion of etrolizum­ab pro­gram, days af­ter dis­sect­ing PhI­II set­back

5 years ago
R&D

The Sanofi/Trans­late team hits the green light on an ear­ly-stage study for their mR­NA Covid-19 vac­cine af­ter see­ing ...

5 years ago
R&D
Coronavirus

Keep­ing an 'im­mi­grant mind­set,' Flag­ship taps a self-pro­fessed no­mad as CEO for their next-gen vi­ral vec­tor up­start

5 years ago
People

Astel­las wa­gers $425M-plus to buy a shot at hatch­ing a 'neur­al dust' break­through in bio­elec­tron­ics

5 years ago
Deals

With all eyes on their Covid-19 drug, Re­gen­eron wins a land­mark ap­proval in Ebo­la

5 years ago
FDA+

Pa­tient death in piv­otal gene ther­a­py tri­al rat­tles Sarep­ta part­ner al­ready fac­ing clin­i­cal hold

5 years ago
R&D
Cell/Gene Tx

Co­di­ak lands on Wall Street in sec­ond shot at IPO, rais­es $83M

5 years ago
Financing

Lu­ca Santarel­li’s PhI­II is good to go, he has a new app to stop Covid-19 from in­fect­ing the da­ta and $110M to pave ...

5 years ago
Financing

Ver­tex shares take a hit as liv­er tox forces the re­search team to scrap a PhII drug for AAT pa­tients. Will we see new ...

5 years ago
R&D

News brief­ing: No­vo eyes the next ki­nas­es in a Finnish start­up; Boehringer In­gel­heim brings a bis­pe­cif­ic to the ...

5 years ago
News Briefing

Months af­ter achiev­ing uni­corn sta­tus, Or­ca steers in­to the fast lane with an RMAT des­ig­na­tion for cell ther­a­py ...

5 years ago
FDA+

Vaxart was served a grand ju­ry sub­poe­na in Ju­ly over its con­tro­ver­sial role in OWS-fund­ed pre­clin­i­cal study

5 years ago
Pharma
FDA+

Cy­cle­ri­on ax­es an­oth­er pro­gram as strug­gles grow for Pe­ter Hecht's Iron­wood spin­out

5 years ago
R&D

Pair of Lancet stud­ies give fi­nal word on a promis­ing Sh­iono­gi an­tibi­ot­ic that turned out to be 'as good' as the ...

5 years ago
R&D

A long-haul biotech with some im­pres­sive back­ers and big goals re­cruits a ma­jor league R&D ex­ec to the helm. What’s ...

5 years ago
People
Startups

Polyphor bags sec­ond grant in two years for a new class of an­tibi­otics to fight drug-re­sis­tant bac­te­ria

5 years ago
Financing

No­var­tis bet $6B on the idea — now Ver­sant, ven­Bio have $45M to birth a plat­form play for ra­dio­phar­ma­ceu­ti­cals

5 years ago
Financing
Startups

Covid-19 roundup: Mod­er­na starts lin­ing up po­ten­tial EU ap­proval for vac­cine; Hahn re­ject­ed White House push to ...

5 years ago
Coronavirus

Third Rock-backed Cedil­la reels in $57.6M for small mol­e­cule pro­grams to fight can­cer

5 years ago
Financing

Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of ...

5 years ago
Deals
Cell/Gene Tx

Canaan rais­es an­oth­er $800M as it launch­es its next fund with an em­pha­sis on biotech

5 years ago
Financing

Eli Lil­ly takes a one-two punch as Covid-19 an­ti­body com­bo study is halt­ed and man­u­fac­tur­ing ops fail in­spec­tion

5 years ago
Outsourcing
Coronavirus

News brief­ing: Re­gen­eron/Sanofi post pos­i­tive PhI­II Dupix­ent da­ta in pe­di­atric asth­ma; Vineti scores $33M Se­ries C ...

5 years ago
News Briefing

Months af­ter re­tir­ing from Genen­tech, Michael Var­ney brings his drug hunt­ing eye to Fra­zier

5 years ago
People
Financing
First page Previous page 790791792793794795796 Next page Last page
A service from the Financial Times